Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-19-017812
Filing Date
2019-03-07
Accepted
2019-03-07 16:57:23
Documents
1
Period of Report
2019-03-04

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4650
  Complete submission text file 0001209191-19-017812.txt   6231
Mailing Address 4747 EXECUTIVE DRIVE SUITE 510 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE SUITE 510 SAN DIEGO CA 92121 858-200-3830
Odonate Therapeutics, Inc. (Issuer) CIK: 0001717452 (see all company filings)

EIN.: 822493065 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 4747 EXECUTIVE DRIVE SUITE 510 SAN DIEGO CA 92121
Business Address
Vacirca Jeff L (Reporting) CIK: 0001724161 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38318 | Film No.: 19666523